arXiv · 2107.03686
A bayesian reanalysis of the phase III aducanumab (ADU) trial
Abstract
In this article we have conducted a reanalysis of the phase III aducanumab (ADU) summary statistics announced by Biogen, in particular the result of the Clinical Dementia Rating-Sum of Boxes (CDR-SB). The results showed that the evidence on the efficacy of the drug is very low and a more clearer view of the results of clinical trials are presented in the Bayesian framework that can be useful for future development and research in the field.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Tommaso Costa, Franco Cauda. 2021-07-08. A bayesian reanalysis of the phase III aducanumab (ADU) trial. https://arxiv.org/abs/2107.03686
Cite the original work for its findings. Save a collection to share your selection of sources.